BJDX Bluejay Diagnostics Inc: Nilai Akuntansi saben Saham

Bluejay Diagnostics (BJDX) aims to implement innovative rapid tests through FDA approval. The company is developing sepsis diagnostic systems for hospitals, targeting the critical care medicine segment. The trend in book value per share confirms current resources, with the indicator standing at 4.75. However, the lack of profitability and challenges in equipment commercialization create significant financial risks.

Book value reflects net assets minus all liabilities, serving as an indicator of financial stability and the business's actual margin of safety. By analyzing the book value per share, an investor assesses the ability of Bluejay Diagnostics (BJDX) to fund the development of rapid tests and navigate regulatory certification using its own resources, thereby minimizing bankruptcy risks during the deployment of portable analyzers into medical centers.